# Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

> **NCT05485909** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 32 (estimated)

## Conditions studied

- Colorectal Cancer Liver Metastases

## Interventions

- **OTHER:** Radiofrequency ablation
- **DRUG:** Regorafenib and Toripalimab Combination

## Key facts

- **NCT ID:** NCT05485909
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-25
- **Primary completion:** 2023-07-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05485909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05485909, "Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05485909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*